Search

Displaying results 2851 - 2860 of 10000 in total
  1. Drug

    M1-c6v1

    go.drugbank.com/drugs/DB18596
    Investigational

    M1-c6v1 is a recombinant oncolytic virus.

  2. Drug

    Anthralin

    go.drugbank.com/drugs/DB11157
    Approved

    Anthralin (1,8‐dihydroxy‐9anthrone, dithranol) is an older anti-psoriatic agent that was first synthesized as a derivative of chrysarobin, obtained from the araroba tree in Brazil over 100 years ago. … Anthralin has also been studied in the treatment of warts, showing promising results [A32307].

    Mixtures: PSORAKS 30 GR KREM, PSORAKS 30 GR FORT KREM
  3. Drug

    Chymopapain

    go.drugbank.com/drugs/DB06752
    ApprovedWithdrawn

    [A32688] Chymopapain was developed by Chart Medcl and FDA approved on November 10, 1982. It is currently discontinued.[L2487] … Chymopapain was first isolated in 1941 from the crude latex derived from the fruit of Carica papaya by squeezing the green papaya while on the plant prior to harvest.

  4. Drug

    Silicon

    go.drugbank.com/drugs/DB12982
    Approved

    Silicon is under investigation in clinical trial NCT00103246 (Photodynamic Therapy Using Silicon Phthalocyanine 4 in Treating Patients With Actinic Keratosis, Bowen's Disease, Skin Cancer, or Stage I or Stage II Mycosis Fungoides).

    Mixtures: Calcium With Mg Zn Mn Cu CR Si and Vit. C & D, Vegetal Silica 5:1
  5. Drug

    Levoketoconazole

    go.drugbank.com/drugs/DB05667
    Approved

    [A244083, A29319, L39573] Levoketoconazole was approved by the FDA on December 30, 2021, and is currently marketed under the registered trademark RECORLEV by Xeris Pharmaceuticals, Inc.[L39563] … [A244078, A244083] [Ketoconazole] has been used both on- and off-label to treat CS due to its ability to inhibit cortisol production.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Inducers
  6. Drug

    Polysilicone-15

    go.drugbank.com/drugs/DB11271
    Approved

    When included in various other cosmetic shampoos, conditioners, or hairsprays the compound also functions as an effective photostabilizer of the product [L2796, L2797, L2799, F87, F88, F89].

  7. Drug

    MK-7145

    go.drugbank.com/drugs/DB11968
    Investigational

    MK-7145 has been used in trials studying the treatment of Hypertension and Renal Insufficiency.

  8. Drug

    Orforglipron

    go.drugbank.com/drugs/DB18964
    ApprovedInvestigational

    [L56122,L56123] It was the first new molecular entity approved under the Commissioner’s National Priority Voucher (CNPV) pilot program, achieving a regulatory decision just 50 days after filing.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesSynonyms: -c]pyridin-5-yl]carbonyl]-5-[(4S)-tetrahydro-2,2-dim, 3-[(1S,2S)-1-({2-(4-fluoro-3,5-dimethylphenyl)-3-({3-[3-(4-fluoro-1-methyl-1H-indazol-5-yl)-2-oxo-2,3-dihydro-1H-imidazol-1-yl]-4-methyl-2,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl}carbonyl)-5-[(
  9. Drug

    MK-886

    go.drugbank.com/drugs/DB16739
    Experimental

    MK-886 is an experimental inhibitor of leukotriene synthesis.

  10. Drug

    MK-4965

    go.drugbank.com/drugs/DB08460
    Experimental

    MK-4965 is an HIV-1 reverse transcriptase inhibitor.